Skip to content
You are now leaving https://www.ionispharma.com to visit

Isis Pharmaceuticals Enters Into an Agreement to Sell $125.0 Million Convertible Subordinated Notes Due 2027 to Refinance Existing $125.0 Million Convertible Subordinated Notes Due 2009